Legal Representation
Attorney
Kristen S. Ruisi
USPTO Deadlines
Application History
20 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Jul 10, 2025 | ASGN | I | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP | Loading... |
| Jul 9, 2025 | ASCK | I | ASSIGNMENT OF OWNERSHIP NOT UPDATED AUTOMATICALLY | Loading... |
| Jun 4, 2025 | EPPA | I | TEAS POST PUBLICATION AMENDMENT RECEIVED | Loading... |
| Mar 3, 2025 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jan 10, 2025 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Jan 10, 2025 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Jan 10, 2025 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Sep 3, 2024 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jul 23, 2024 | TMBN | T | TTAB RELEASE CASE TO TRADEMARKS | Loading... |
| Jun 2, 2024 | ETOP | T | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | Loading... |
| Apr 22, 2024 | APET | A | ASSIGNED TO PETITION STAFF | Loading... |
| Mar 11, 2024 | EPPA | I | TEAS POST PUBLICATION AMENDMENT RECEIVED | Loading... |
| Feb 20, 2024 | ETOF | T | EXTENSION OF TIME TO OPPOSE RECEIVED | Loading... |
| Jan 23, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Jan 23, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 3, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Dec 21, 2023 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 20, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Apr 18, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Mar 30, 2023 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Medicines, pharmaceutical preparations, chemico-pharmaceutical preparations, biological preparations for medical purposes, chemical preparations for medical purposes, all of the foregoing for the treatment of cancer and rheumatoid arthritis; diagnostic biomarker reagents for medical purposes; pharmaceuticals for the treatment of cancer, autoimmune and inflammatory diseases and infectious diseases; none of the aforesaid for or in relation to products, preparations and/or substances acting on the central nervous system, including pain, headache and migraine
Classification
International Classes
005